Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 2 (MAGI-2) is a scaffold protein encoded by the MAGI2 gene, characterized by two WW domains, multiple PDZ domains, and a guanylate kinase–like domain[1][2][4][5]. It is a member of the membrane-associated guanylate kinase (MAGUK) family and is highly expressed in the brain and in glomerular podocytes in the kidney, where it plays a pivotal role in assembling signaling complexes at synaptic junctions and within the slit diaphragm of the glomerular filtration barrier[1][2][5]. MAGI-2 directly interacts with nephrin and other junctional proteins, and is necessary for maintaining podocyte structure and preventing proteinuria and glomerulosclerosis[2][3]. Mutations or downregulation of MAGI-2 are associated with hereditary and steroid-resistant nephrotic syndrome as well as certain cancers, and its expression level serves as a sensitive marker for podocyte injury in both experimental models and human kidney disease[2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Membrane-associated guanylate kinase, WW and PDZ domain-containing protein 2 (MAGI-2).